Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
breast cancer
Pharma
FDA approves AZ/Daiichi's Enhertu in 1st-line breast cancer
The FDA has approved Enhertu combined with Roche’s Perjeta as a first-line treatment for unresectable or metastatic HER2-positive breast cancer.
Kevin Dunleavy
Dec 15, 2025 4:15pm
Lilly shifts oral SERD hopes to its largest oncology trial ever
Dec 12, 2025 11:45am
AZ, Gilead program helped Black breast cancer patients: study
Dec 10, 2025 3:00pm
Pfizer details Tukysa's 1st-line data in HER2 breast cancer
Dec 10, 2025 8:15am
Poherdy, first biosimilar to Roche's Perjeta, scores FDA nod
Nov 14, 2025 10:52am
Merck grows more ambitious about 'workhorse' TROP2 ADC
Oct 20, 2025 4:00pm
